Patient-reported involvement of the eighth cranial nerve in giant cell arteritis by Saravanan V et al.
ORIGINAL ARTICLE
Patient-reported involvement of the eighth cranial nerve in giant
cell arteritis
Vadivelu Saravanan1 & Susan Pugmire1 & Mavis Smith1 & Clive Kelly1
Received: 26 June 2019 /Revised: 29 July 2019 /Accepted: 8 August 2019
# The Author(s) 2019
Abstract
Introduction The frequency of eighth nerve lesions in patients with giant cell arteritis (GCA) has rarely been examined.
However, sudden onset deafness has been recorded as a presenting feature of GCA on several occasions. This study sought to
establish how common this and other symptoms of eighth nerve involvement are in a large retrospective survey.
Methods We contacted 170 patients with GCA and 250 matched PMR patients, inviting them to participate in a questionnaire
survey of symptoms of eighth nerve dysfunction. We compared the presence of deafness, tinnitus, loss of balance and vertigo in
both groups and examined the relationship between the onset of these symptoms and other features of GCA.
Results A total of 317 patients were recruited. The percentage of patients with symptoms of possible vestibulocochlear
disease prior to commencement of steroid therapy was significantly greater among GCA patients than PMR patients for all
domains. Hearing loss which was twice as common in GCA as in PMR (53% vs 26%) [p = 0.001]. Deafness was
concurrent in 35% of GCA patients with other symptoms and 45% reported colocation with headache. Recovery with
steroids occurred in 56% of these.
Conclusion Symptoms of eighth nerve dysfunction are present in over half of patients with GCA. Recovery with steroids was
predicted by concurrence with headache in terms of both timing and location. It appears that eighth nerve involvement, especially
acute hearing loss, is a not infrequent feature of GCA and often responds well to steroid therapy. Clinicians should enquire about
these symptoms when evaluating a patient for possible GCA.
Key Points
• Deafness is a frequent presenting feature of giant cell arteritis.
• Vertigo, tinnitus and loss of balance are also often reported by GCA sufferers.
• Steroid therapy is more likely to relieve these symptoms if they are ipsilateral and concurrent with headache.
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Introduction
Giant cell arteritis (GCA) is a serious condition, with a prev-
alence of between 17 and 154 per 10,000 population in the
UK [1, 2]. Northern Europe has the highest reported preva-
lence and women are affected at least twice as often as men
[3]. GCA is a systemic vasculitis of medium and large arteries
often with ophthalmic involvement, including ischemic optic
neuropathy, retinal artery occlusion and ocular motor cranial
nerve palsies. GCA usually affects the superficial temporal
arteries and the ophthalmic, occipital, vertebral, posterior cil-
iary and proximal vertebral arteries [2]. Common symptoms
include temporal tenderness, jaw claudication and double-
vision or occasionally loss of vision. Approximately 20% of
cases in total describe visual disturbances [3].
Cranial nerve palsies have been described in 2–15% of
patients with GCA [4], although these rarely affect more than
one cranial nerve. The third nerve is the most commonly af-
fected, but involvement of the fourth, fifth, sixth and eighth
nerves have also been reported [4]. Over the past 25 years,
only 1.5% of all GCA cases have reported loss of hearing and/
or vertigo as a symptom [5]. However, in clinical practice,
many patients report loss of hearing or tinnitus commensurate
with the onset of GCA symptoms, and many patients describe
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at least partial resolution with the commencement of steroid
treatment. By contrast vestibulo-auditory manifestations were
quite common in a prospective study [6]. Common symptoms
were unilateral or bilateral hearing loss, vertigo and tinnitus.
In total, 64% had subjective hearing impairment, 52% had
vertigo and 50% had tinnitus. These were reversible in most
cases following steroid therapy [6].
Polymyalgia rheumatica (PMR) is a condition that causes
muscle stiffness in patients around the neck and shoulders. It
is rare under the age of 50 and usually affects patients over the
age of 65 years. PMR is characterised by proximal muscle
stiffness, usually in the morning, that lasts for more than
45 min. It is estimated that 1 in every 1200 people in the
UK will develop the condition annually [7]. Approximately
one in five patients of these then develop GCA (NHS Choices
2017). Up to 50% of patients with GCA also have PMR [8].
Despite the dearth of published evidence relating to symp-
toms such as loss of hearing and tinnitus in GCA, frequent
reports by patients and the results of a single prospective sur-
vey [6] led us to conclude that it is appropriate to investigate
the involvement of the vestibulocochlear nerve, as part of the
possible spectrum of disease seen in GCA, using PMR with-
out GCA patients as controls.
Methods
Aims and objectives
The study aimed to investigate the hypothesised connection
between patient-reported symptoms of hearing loss and other
potential symptoms of eighth nerve involvement with the on-
set of GCA. We aimed to gauge the frequency of such symp-
toms within the GCA patient population, using patients with
PMR and no evidence of GCA as controls, and thereby de-
duce the frequency of involvement of the vestibulocochlear
nerve in patients with GCA.
The objective was to survey 250 patients with GCA
for symptoms of possible vestibulocochlear dysfunction
and a further 250 age- and sex-matched control patients
with PMR but no GCA. We intended to calculate the
prevalence of each of four possible symptoms in both
populations. Furthermore, we wished to assess the rela-
tionship between the site of any auditory symptoms (ip-
silateral or bilateral) and the site of headache, together
with the temporal relationship between them. We wanted
to assess the response of all vestibulocochlear symptoms
to steroid therapy and to assess the potential association
between colocation (ipsilateral headache and deafness
/tinnitus) and steroid responsiveness. We also wished to
explore the relationship between concurrence (synchro-
nous onset of headache and auditory symptoms) and ste-
roid responsiveness. We hoped that this would allow
patients and their clinicians to identify the disease in its
fullest manifestations more rapidly, offering the potential
to improve treatment outcomes.
The study was conducted via a Likert scale and narrative
questionnaire. Participants were identified through the regis-
tered charity PMR-GCA UK Support Group who funded the
study. The Charity holds a comprehensive database of pa-
tients, who have previously consented to be contacted for
research activities.
Inclusion and exclusion criteria
Inclusion criteria were defined as:
& 50 years old or above, diagnosed with GCA (active) or
PMR (controls)
& Contact information contained within the funders database
& Able and willing to complete a paper version
questionnaire
Exclusion criteria were defined as:
& Under 50 years of age or not currently diagnosed with
GCA or PMR
& Insufficient contact information contained within the
funders database
& Unable to complete a paper questionnaire
Recruitment
A named member of the funders team (MS) identified patients
and sent a Participant Information Sheet and Questionnaire via
the post. A return addressed envelope was contained in the
research pack. Completed questionnaires were returned to the
Chief Investigator based at the Gateshead Health NHS
Foundation Trust. This process has been tested and validated
in the pilot phase of the study. The questionnaire shall not
collect any identifiable patient data and for the protection of
the participants, the Chief Investigator shall not have access to
the funders database. All questionnaires were anonymised via
a study number known only to the funders.
Materials
It was deemed most appropriate to conduct the questionnaire
via paper-based postal distribution. Because of the significant
age of the patients involved, this was felt to carry a higher
likely response rate than an online questionnaire. Hence, po-
tential participants were identified by the funder and a re-
search pack sent in the post. The pack contained a participant
Information Sheet, questionnaire and return addressed enve-
lope. Patients wishing to participate in the study were given
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3 months to return their completed questionnaire to the Chief
Investigator. All paper questionnaires are retained in a locked
cabinet. All data are to be archived after the official close of
the study for 5 years, as per local archiving policies.
Data analysis
Information from the questionnaires was collated into a
password-protected Excel spreadsheet. It was held on an
NHS Server only. Data entry was to be performed by a
member of the study team (SP). Data were checked by
the Chief Investigator for accuracy. Each questionnaire
was provided with a unique identification study code on
receipt.
It was not possible to contact participants to complete any
blank fields. Therefore, it was only deemed acceptable if a
questionnaire was completed in at least 75% of fields.
Answers were analysed using a variety of descriptive statistics
and narrative-based answers were analysed using qualitative
approaches.
Ethical issues and consent
As a condition of inclusion within the database holding the
details of potential participants, prior written consent to
postal surveys had been obtained. Under these circum-
stances, it was deemed that a returned questionnaire would
be taken as implied consent. This approach was approved
by the Health Research Authority and Research Ethics
Committee. The patient information sheet (PIS) explained
that there was no direct benefit to participants, nor any
perceived potential for harm. However, subsequent pa-
tients may benefit by earlier and more accurate diagnosis
with the potential for more rapid and potentially effective
therapeutic intervention.
Statistics
The study aimed to recruit 500 participants. It was es-
timated that this is feasible with a 75% response rate in
comparison to the number of participants currently on
the Charities database [9].
However, it is noted that the response rate may be
greater or lower than expected. To ensure that sufficient
respondents are included in the study, the margin of
error is calculated dependent upon the number of re-
spondents [10].
It is worth noting that “the minimum sample size needed
to evaluate features with an acceptable tolerable error (re-
lating to the studies research question and objectives, as-
suming a relative tolerable error of 5%, a coefficient of
variation (C) of a population of 5% and a pairwise corre-
lation coefficient p (rho) of 0.5) is 231 participants, who
provide calculations in table format allowing for a 5-item
Likert scale. However, due to the population being finite,
the sample size must be adjusted [9]:
n ¼ n0N
n0 þ N−1ð Þ ¼
231 Unknown at presentð Þ
231þ Unknown−1ð Þ ¼ ??
Comparisons between the GCA and PMR groups were
made using Pearson’s chi-square test because of the uneven
numbers of returned questionnaires from within the two
groups.
Results
The intention had been to recruit 250 patients with each of
GCA and PMR but we failed to achieve this. Questionnaires
were sent to only 170 patients with GCA, while they were
delivered to 250 with PMR. This difference was due to the
difficulty in identifying reliable diagnoses in sufficient pa-
tients. However, response rates between the two groups were
very similar at 74% among patients with GCA and 76% for
PMR patients. This led to a total of 317 patients recruited to
the study. Of these, 128 had giant cell arteritis and 189 had
polymyalgia rheumatica. Sufficient patients were recruited to
meet the statistical requirements for significance.
The median age of patients at diagnosis did not differ be-
tween GCA and PMR (71 years vs 70 years). The percentage
of male patients was also similar in both groups (8% vs 9%).
As expected, the median initial dose of prednisone was greater
in patients with GCA than in those with PMR (60 mg vs
15 mg). The total duration of therapy with prednisone at the
time of data collection was not significantly different between
GCA and PMR patients (18 months vs 17 months), and 72%
of patients in each group were still taking prednisone at the
time of the study. These data are shown in Table 1.
The percentage of patients with symptoms of possible
vestibulocochlear disease prior to commencement of steroid
therapy was significantly greater among GCA patients when
compared to those with PMR. This observation extended
across all four symptom domains and is shown in Table 2.
Specifically, patients with GCA reported hearing loss in over
half of cases which were twice as often as reported by patients
with PMR (53% vs 26%) [p = 0.001].
Tinnitus was also reported significantly more commonly
among GCA patients than by those with PMR, although the
difference was less marked (51% vs 39%) [p = 0.02]. Loss of
balance was recorded by well over half of patients with GCA,
and again this was significantly less frequent among those
with PMR (57% vs 38%) [p = 0.01]. Finally, vertigo was the
least frequently reported symptom but was still almost twice
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as commonly reported among those with GCA than those with
PMR (39% vs 22%) [p = 0.003].
The data relating to the timing of potential vestibulocochlear
symptoms with the rheumatological diagnosis was important.
Thirty-five per cent of patients with GCA and hearing loss stat-
ed that their deafness was concurrent with the onset of other
symptoms of GCA, and 45% said that this was ipsilateral and
unilateral with headache. Importantly, recovery with steroids in
line with other symptoms was reported by only 20% of GCA
patients overall but was much higher at 56% among those with
both concurrent symptoms and colocation. By comparison, pa-
tients with PMR who reported hearing loss had less symptom
concurrence (12%) and little recovery with steroids (5%).
Differences between GCA and PMR were significant
[p = 0.01].
Among those with GCA and tinnitus, symptoms concurred
with diagnosis in 33% and were purely ipsilateral with head-
ache in 42% of cases. However, improvement with steroids
was only reported in 14% overall. Again, those patients with
both concurrent symptoms and ipsilateral location had a much
higher steroid response rate of 42%. Corresponding figures for
those with PMR and tinnitus were 28% for symptom concur-
rence while recovery with steroid recovery was reported in
just 9%.
In those GCA patients who recorded loss of balance, this
was reported to have occurred at the same time as other symp-
toms in 53% but improved with steroid therapy in only 27%.
Comparative figures for PMR patients were not significantly
different at 45% and 17% respectively.
Finally, vertigo among patients with GCAwas concurrent
with other clinical features in 50% but recovered with steroids
in just 17%. By comparison, among PMR patients, 28% had
symptom concurrence while 22% reported steroid-related
recovery, but with poor correlation. Although vertigo was sta-
tistically more likely to be concurrent with other symptoms in
GCA patients, the responsiveness of vertigo to steroid therapy
did not differ significantly between GCA and PMR.
These data are summarised in Table 3.
Discussion
Cranial nerve palsies are well recognised as complications of
GCA but these most commonly affect the nerves responsible
for eye movements with third and sixth nerve palsies most
commonly reported [11–23]. A good response to steroids is
usually providing the diagnosis is made promptly. Our study
has demonstrated that involvement of the eighth nerve is also
not infrequently reported among patients with GCA. Deafness
and tinnitus were the main symptoms reported by our patients
and each occurred in over half of patients with GCA. These
results are very similar to those reported in the one published
prospective study in this area which showed similar preva-
lence figures for deafness and tinnitus [6]. This reported
symptoms of unilateral or bilateral hearing loss, vertigo and
tinnitus. Subjective hearing impairment was recorded in 64%,
52% had vertigo and 50% had tinnitus. The symptoms of
vestibular dysfunction were reversible in most cases following
steroid therapy, while only 27% of GCA patients had hearing
improvement after 3 months of steroids.
Although there have been several previous case reports and
small series describing deafness and tinnitus in GCA [24–29],
these amount to no more than 20 patients in total over nearly
50 years. Vertigo and dizziness have also been described in
GCA in a small number of patients reported retrospectively
[30]. The mechanism of vestibulocochlear involvement in gi-
ant cell arteritis is unclear but is thought to be secondary to
inflammatory involvement of the vertebrobasilar system or
the terminal cochleovestibular vessels [28]. The literature
has not translated into a high level of awareness of this com-
plication of the disease amongst most clinicians, but it appears
that patients are much more aware of it. We suggest that cli-
nicians need to be conscious of the association of eighth nerve
dysfunction and GCA and that this may aid earlier diagnosis
and prompt initiation of therapy with better patient-related
outcomes.
Table 1 To compare the demography of patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) at point of study entry
Mean age
(years)
Number (N)
(%) male
Duration of symptoms
(months)
Initial dose of
Prednisone (mg)
N (%) still on
steroid
GCA 71 6 (8) 18 60 50 (72)
PMR 70 6 (9) 17 15 50 (72)
P value – – – 0.001 –
Table 2 To compare the prevalence of recorded vestibulocochlear
symptoms between 128 patients with giant cell arteritis (GCA) and 189
with polymyalgia rheumatica (PMR) in numbers (percentages) of total
GCA PMR P value
Hearing loss 68 (53%) 49 (26%) 0.001
Tinnitus 65 (51%) 74 (39%) 0.02
Loss of balance 73 (57%) 72 (38%) 0.01
Vertigo 50 (39%) 41 (22%) 0.003
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Several studies have shown that GCA patients with elevat-
ed inflammatory markers have a lower risk of cranial ischae-
mic symptoms compared to those with lower inflammatory
markers [31]. Pretreatment ESRs and CRP levels are inversely
correlated with the risk of visual symptoms in GCA. One
plausible explanation is that patients with cranial ischaemia
present sooner, prior to developing a strong systemic inflam-
matory response [31]. Hence, awareness of the full range of
symptoms suggesting possible intra-cranial involvement in
GCA is essential if clinicians are to optimise their patients’
outcome. Our data did not allow for differentiation between
central and peripheral eighth nerve involvement. The presence
of vertebrobasilar insufficiency and resulting cerebellar syn-
drome also increases with age and may have accounted for a
significant percentage of vestibulocochlear symptomatology
among our patients. Given that auditory acuity declines with
age, the use of PMR patients as controls is essential in this
study of patients with a mean age of 70 to account for such
background pathology.
The marked difference in both the comparative rates be-
tween patients with GCA and PMR and in the responsiveness
of these symptoms to steroid therapy in our study is therefore
of great clinical interest. Clearly, features such as loss of bal-
ance and vertigo are less specific for eighth nerve dysfunction
than is deafness and may have many other potential causes.
Although both appeared more frequently among those with
GCA, the reported responsiveness of these symptoms to ste-
roid therapy was not as good as that of hearing loss, which is at
odds with the prospective data [6].
The association between both colocation and concurrence
of symptoms and subsequent steroid responsiveness is highly
pe r t i n en t . Those pa t i en t s whose symp toms o f
vestibulocochlear dysfunction were most likely to be directly
related to their GCA diagnosis on the basis of their location
and timing were nearly three times more likely to report an
improvement in these symptoms on commencing steroid ther-
apy. This emphasises the importance of a thorough history of
this relationship to define the probability of such symptoms
being directly attributable to the GCA and the relevance of
these findings to the subsequent prognosis for recovery.
A major advantage of our study is its size. The literature
consists mainly of scattered case reports so a substantial study
across the UK constitutes a much larger evidence base to
guide clinicians. The strong statistical association we report
between symptoms of eighth nerve dysfunction and GCA
should reinforce the importance of assessing symptoms of
possible dysfunction in patients where GCA is suspected.
The major limitation of our study is its retrospective nature
and the fact that it relied entirely on patient recall as collected
in questionnaire form. This approach is more likely to reduce
rather than increase the estimated prevalence as elderly pa-
tients are more likely to forget symptoms rather than to invent
them in this setting. We also accept that the lack of a physical
examination to confirm or refute patient description of their
symptoms is a further limitation of our study. However, given
the wide geographic distribution of our patients included in
the survey, this was the only practical way to contact the large
numbers required for statistical significance. There is no rea-
son to suggest this limitation could account for the significant
observed differences between those patients with GCA and
those with PMR. The similarity between our data and that
reported in the only prospective study to date provides further
reassurance about the likely accuracy of our retrospective
data.
The dose of steroid used was much higher in those patients
with GCA than those treated for PMR, as would be expected.
We considered whether this could account for any of the ob-
served increase in prevalence figures reported by patients with
GCA as compared to those with PMR. This seemed to be
highly unlikely as steroids are used to treat acute idiopathic
hearing loss [32], which should therefore be less likely to
persist in those patients who received higher doses of predni-
sone. However, it is interesting to speculate that such symp-
toms may also relate to an auto-immune vasculitis that could
overlap and might even represent a limited form of GCA.
In summary, we report a high prevalence of self-recorded
features of eighth nerve dysfunction among patients with
GCA. Hearing loss and tinnitus are most strongly associated
with other clinical features of the disease and are more likely
to respond to the commencement of high-dose steroids.
Table 3 To compare both the concurrence of vestibulocochlear symptoms with other symptoms and steroid responsiveness (among those with
concurrence) between 128 patients with giant cell arteritis (GCA) and 189 with polymyalgia rheumatica (PMR) as numbers (percentages) of total
Symptom concurrence Steroid response P values
GCA PMR GCA PMR
Hearing loss 68 (53%) 23 (12%) 72 (56%) 9 (5%) 0.01, 0.01
Tinnitus 43 (33%) 52 (28%) 54 (42%) 17 (9%) NS, 0.01
Loss of balance 68 (53%) 86 (45%) 35 (27%) 32 (17%) NS, NS
Vertigo 64 (50%) 52 (28%) 22 (17%) 27 (15%) 0.04, NS
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